Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

Atossa Therapeutics, a clinical stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other areas of significant unmet medical need in oncology, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vice President of Investor and Public Relations at Atossa, will engage in a virtual fireside chat on Wednesday, October 16, 2024, at 12:00 p.m. EDT.

The company, traded on Nasdaq under the ticker ATOS, invites interested parties to register and access the live webcast of the conference through a provided link. This event presents an opportunity for investors and stakeholders to gain insights into Atossa's current developments and future prospects in the oncology field.

News Market Reaction – ATOS

+0.70%

+0.70% Session move

In the trading session that priced this news, ATOS gained 0.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Interested parties can register and access the live webcast for the conference here.  

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Michael Parks
Vice President, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com

FAQ

When is Atossa Therapeutics (ATOS) presenting at the 2024 Maxim Healthcare Virtual Summit?

Atossa Therapeutics (ATOS) is presenting at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 12:00 p.m. EDT.

Who will be representing Atossa Therapeutics (ATOS) at the 2024 Maxim Healthcare Virtual Summit?

Michael Parks, Vice President of Investor and Public Relations at Atossa Therapeutics, will be representing the company in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit.

What is the main focus of Atossa Therapeutics (ATOS) in drug development?

Atossa Therapeutics (ATOS) is focused on developing innovative medicines in areas of significant unmet medical need in oncology, with a particular emphasis on breast cancer.

How can interested parties access the Atossa Therapeutics (ATOS) presentation at the 2024 Maxim Healthcare Virtual Summit?

Interested parties can register and access the live webcast of Atossa Therapeutics' (ATOS) presentation at the 2024 Maxim Healthcare Virtual Summit through a link provided by the company.